ValuEngine Lowers Rockwell Medical (RMTI) to Hold

Share on StockTwits

ValuEngine lowered shares of Rockwell Medical (NASDAQ:RMTI) from a buy rating to a hold rating in a report released on Wednesday, ValuEngine reports.

A number of other brokerages have also issued reports on RMTI. Ifs Securities upgraded shares of Rockwell Medical from an outperform rating to a strong-buy rating in a research note on Monday, March 18th. HC Wainwright initiated coverage on shares of Rockwell Medical in a research note on Monday, May 13th. They issued a buy rating and a $11.00 target price on the stock.

NASDAQ:RMTI opened at $4.63 on Wednesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.56 and a quick ratio of 3.24. Rockwell Medical has a 1-year low of $2.19 and a 1-year high of $6.88.

Rockwell Medical (NASDAQ:RMTI) last issued its earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03. The business had revenue of $15.56 million for the quarter, compared to analyst estimates of $16.90 million. Rockwell Medical had a negative net margin of 55.09% and a negative return on equity of 144.07%. Research analysts anticipate that Rockwell Medical will post -0.51 EPS for the current fiscal year.

In related news, insider David S. Richmond bought 5,869 shares of the business’s stock in a transaction dated Wednesday, March 27th. The shares were acquired at an average price of $5.59 per share, for a total transaction of $32,807.71. Following the purchase, the insider now owns 177,930 shares in the company, valued at approximately $994,628.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider David S. Richmond bought 4,643 shares of the business’s stock in a transaction dated Thursday, May 9th. The stock was bought at an average price of $5.65 per share, for a total transaction of $26,232.95. Following the purchase, the insider now owns 178,436 shares in the company, valued at approximately $1,008,163.40. The disclosure for this purchase can be found here. Corporate insiders own 18.20% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. acquired a new stake in Rockwell Medical during the fourth quarter worth about $27,000. Quantamental Technologies LLC raised its stake in Rockwell Medical by 194.3% during the first quarter. Quantamental Technologies LLC now owns 5,301 shares of the company’s stock worth $30,000 after acquiring an additional 3,500 shares during the period. Starfire Investment Advisers Inc. acquired a new stake in Rockwell Medical during the fourth quarter worth about $43,000. AdvisorNet Financial Inc acquired a new stake in Rockwell Medical during the fourth quarter worth about $51,000. Finally, BNP Paribas Arbitrage SA raised its stake in Rockwell Medical by 5,456.7% during the first quarter. BNP Paribas Arbitrage SA now owns 9,891 shares of the company’s stock worth $56,000 after acquiring an additional 9,713 shares during the period. Institutional investors and hedge funds own 18.81% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis.

Recommended Story: Why is total return important?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.